The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
DNA-damage response-umbrella study of the combination of ceralasertib and olaparib, or ceralasertib and durvalumab in advanced biliary tract cancer: A phase 2 trial-in-progress.
 
Jee Sun Yoon
No Relationships to Disclose
 
Jin Won Kim
No Relationships to Disclose
 
Ji-Won Kim
No Relationships to Disclose
 
Tae-Yong Kim
No Relationships to Disclose
 
Ah-Rong Nam
No Relationships to Disclose
 
Ju-Hee Bang
No Relationships to Disclose
 
Hye-Rim Seo
No Relationships to Disclose
 
Jae-Min Kim
No Relationships to Disclose
 
Kyoung Seok Oh
No Relationships to Disclose
 
Peter G. Mortimer
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Simon Smith
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Do-Youn Oh
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; Merck Serono; Novartis; Taiho Pharmaceutical; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Lilly; MSD; Novartis; SERVIER